Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Nurix Therapeutics, Inc. despite lower revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to show a quarterly loss of $0.74 per share, reflecting a year-over-year change of +2.6%, while revenues are projected to be $13.17 million, down 20.6% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 3.94% lower in the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4][10]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -20.47%, which indicates a bearish outlook [10][11]. Historical Performance - Nurix Therapeutics has only beaten consensus EPS estimates once in the last four quarters, with a recent surprise of -11.94% when it reported a loss of $0.75 per share against an expected loss of $0.67 [12][13]. Conclusion - The combination of a negative Earnings ESP and a Zacks Rank of 3 makes it challenging to predict a positive earnings surprise for Nurix Therapeutics, suggesting that the stock may not be a compelling candidate for an earnings beat [11][16].

Core Insights - Nurix Therapeutics has announced an exclusive licensing agreement with Sanofi for a previously undruggable transcription factor targeting autoimmune diseases, which is a central regulator of inflammation [1][2] - The collaboration has generated a total of $105 million in payments to Nurix, with the potential for an additional $465 million in development, regulatory, and commercial milestones, along with future royalties [1][2] - Nurix's DEL-AI drug discovery platform has successfully identified novel agents for this target, enhancing the drug discovery pipeline for autoimmune diseases [2] Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [3][4] - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), as well as multiple preclinical programs [3][4] - Nurix has received a total of $460 million from various partners, including the $105 million from the Sanofi collaboration, which is crucial for expanding its drug discovery pipeline [2][3]

Core Insights - Nurix Therapeutics, Inc. is set to present preclinical data from its DEL-AI platform and various degrader programs at the AACR 2025 Annual Meeting, highlighting its focus on targeted protein degradation medicines [1][8] Presentation Details - The oral presentation titled "DEL-AI: Proteome-wide in silico screening of multi-billion compound libraries using machine learning foundation models" will be presented by Paul Novick, Ph.D. on April 28, 2025 [2] - Another oral presentation titled "Identification of selective, orally bioavailable Aurora A degraders for treatment of pediatric and adult cancers" will be presented by Ryan Rountree, Ph.D. on April 29, 2025 [2] - The poster presentation titled "NRX-0305: a pan-mutant BRAF degrader with broad preclinical efficacy, brain penetrance, and synergistic potential with MEKi across class 1/2/3 BRAF-mutant cancers" will be presented by Alexandra 'Sasha' Borodovsky, Ph.D. on April 28, 2025 [3] - The poster presentation titled "NX-5948 is a CNS-penetrant catalytic Bruton's tyrosine kinase (BTK) degrader that breaks established design rules for CNS drugs" will be presented by Wylie Palmer, Ph.D. on April 30, 2025 [3] About DEL-AI - DEL-AI is Nurix's proprietary discovery platform that utilizes advanced machine learning for drug discovery, enabling rapid generation of degraders and degrader antibody conjugates (DACs) [4] - The platform leverages hundreds of billions of DEL compound binding signatures from thousands of affinity screens, allowing for the identification of binders for various pharmaceutical targets [4] About Bexobrutideg (NX-5948) - Bexobrutideg is an investigational, orally bioavailable, brain-penetrant small molecule degrader of BTK, currently in a Phase 1 clinical trial for patients with relapsed or refractory B cell malignancies [5] About NRX-0305 - NRX-0305 is a selective, orally bioavailable mutant-specific BRAF degrader showing potent anti-tumor activity in various preclinical models, including those with CNS disease and treatment resistance [6][7] About Aurora A Kinase - Aurora A kinase (AURKA) is frequently overexpressed in various cancers, and Nurix has developed bifunctional targeted protein degraders to address the limitations of traditional inhibitors [7] Company Overview - Nurix Therapeutics focuses on the discovery, development, and commercialization of targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [8] - The company has a clinical-stage pipeline that includes degraders of BTK and inhibitors of CBL-B, along with multiple preclinical programs in collaboration with major pharmaceutical companies [8]

Core Insights - The FDA has granted Orphan Drug Designation to bexobrutideg (NX-5948) for the treatment of Waldenström macroglobulinemia, highlighting its potential as a new therapeutic option for patients with this rare disease [1][3][2] - Bexobrutideg is a first-in-class Bruton's tyrosine kinase (BTK) degrader, which is currently undergoing Phase 1a/b clinical trials for relapsed or refractory B-cell malignancies [1][5] - The designation provides benefits such as tax credits for clinical testing, waiver of FDA application fees, and seven years of market exclusivity upon approval [2] Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [8] - The company is advancing multiple first-in-class or best-in-class degraders and has a partnered drug discovery pipeline with collaborations involving Gilead Sciences, Sanofi, and Pfizer [8] - Nurix's innovative approach includes a fully AI-integrated discovery engine and expertise in ligase, positioning the company to lead in the development of degrader-based treatments [8] Product Details - Bexobrutideg is an investigational, orally bioavailable, brain-penetrant small molecule that has shown early promise in safety and efficacy for patients with Waldenström macroglobulinemia [5][1] - The ongoing Phase 1b expansion cohort continues to enroll patients, with additional clinical data expected to be shared in 2025 [5] - The unique suffix "deg" in the drug's nonproprietary name reflects its novel mechanism of action, differentiating it from traditional inhibitors [3][4] Disease Context - Waldenström macroglobulinemia is a rare type of non-Hodgkin's lymphoma with an incidence of approximately 1,200 to 1,900 cases annually in the U.S., affecting around 12,000 to 19,000 patients currently [7][6] - The disease is characterized by the production of monoclonal IgM, leading to various health complications, and there are currently no approved therapies for patients after BTK inhibitor treatment [7][6]

Core Insights - Nurix Therapeutics, Inc. has appointed Dr. Roy D. Baynes to its board of directors, bringing over 22 years of clinical leadership experience in hematology and oncology [1][2] - Dr. Baynes has been a trusted advisor to Nurix since 2023 and is expected to contribute significantly to the company's pipeline development in oncology and autoimmune indications [2] - Nurix focuses on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [3] Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted protein degradation medicines [3] - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on potentially first-in-class or best-in-class treatments [3] - Nurix has collaborations with major pharmaceutical companies such as Gilead Sciences, Sanofi, and Pfizer, retaining options for co-development and profit sharing in the U.S. for multiple drug candidates [3]

SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today the appointment of Roy D. Baynes, MB.Bch., M.Med., Ph.D., to its board of directors. Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon Therapeutics, has had a distinguished career in hematology and oncology and ov ...

SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on February 11, 2025, the company granted inducement awards to nine new employees. The grants were made pursuant to Nurix's ...

SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the O ...

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.77 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.94%. A quarter ago, it was expected that this company would post a loss of $0.67 per share when it actually produced a loss of $0.67, delivering no surprise.Over the last four quarters, the company has surpass ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________ __________________FORM _____________________________10-K ____________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD ...